The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...

Seniors have a 61% higher risk of stroke if their parents divorced when they were children or teenagers, researchers reported in a study published Wednesday in the journal PLOS One.

The rink is set at the U.S. Figure Skating Championships in Wichita, Kansas — and the competition is already heating up!

Polyrizon is progressing with preparations for its planned 2025 clinical trial. The designated manufacturing facility is equipped to meet the clinical trial material (CTM) requirements, ensuring ...